MWNA
VTGN icon

Marshall Wace North America’s VistaGen Therapeutics VTGN Stock Holding History

Marshall Wace North America’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-94,282
Closed -$6.02M – 1811
2021
Q1 		$6.02M Buy
+94,282
New +$6.29M 0.02% 514

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace North America's VTGN Position: Q2 2021 in Review

Marshall Wace North America sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 94,282 shares — an estimated $6.02M sold.

Marshall Wace North America first reported a position in VTGN in Q1 2021 and held it in 1 quarter. The position peaked at $6.02M in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

  • Marshall Wace North America reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 94,282 VistaGen Therapeutics shares in Q2 2021, an estimated $6.02M.
  • Marshall Wace North America first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's VistaGen Therapeutics position peaked at $6.02M in Q1 2021.
  • 101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.